Sensei Biotherapeutics’ (FTH) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report published on Tuesday,Benzinga reports. BTIG Research currently has a $55.00 target price on the stock.

Other equities research analysts have also issued reports about the company. William Blair initiated coverage on Sensei Biotherapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Guggenheim began coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price target for the company. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Finally, TD Cowen initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Buy” and an average price target of $56.25.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $18.75 on Tuesday. The stock has a 50 day moving average price of $29.07. The stock has a market capitalization of $484.50 million, a P/E ratio of -0.13 and a beta of -0.29. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, research analysts predict that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the second quarter worth $3,610,000. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. Bank of America Corp DE grew its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.